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Abstract 
 
Objectives: Adolescents with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis 
(CFS/ME) appear to be more likely to experience anxiety and/or depression using Patient 
Reported Outcome Measures (PROMs). However, we do not know how accurate these are at 
detecting problems in this patient group given the primary symptom of fatigue. We aimed to 
accurately determine the prevalence of anxiety/depression using gold standard diagnostic 
interviews and evaluate the accuracy of PROMs measuring mood disorders in this patient 
group. 
Study Design: Cross-sectional epidemiological study in a specialist tertiary paediatric 
CFS/ME service, England. The participants were164 12-18-year olds with clinician 
confirmed CFS/ME, and their parents. The measures were a semi-structured diagnostic 
interview, the Kiddie Schedule for Affective Disorders and Schizophrenia, K-SADS and 
questionnaires (Revised Children’s Anxiety and Depression Scale, RCADS; Spence 
Children’s Anxiety Scale, SCAS; Hospital Anxiety and Depression Scale, HADS). Parents 
completed the RCADS-P.  
Results: 35% met the criteria for at least one common mental health problem. 20% had major 
depressive disorder, and 27% an anxiety disorder, with social anxiety, and generalised 
anxiety being most common. There was high co-morbidity, with 61% of those who were 
depressed also having at least one anxiety disorder. The questionnaires were moderately 
accurate (AUC > 0.7) at detecting clinically significant anxiety/depression, although only the 
RCADS-anxiety reached the predefined 0.8 sensitivity, 0.7 specificity target.  
Conclusions: Mental health problems are particularly common amongst adolescents with 
CFS/ME. Most screening tools were not sufficiently accurate at detecting clinically 
significant anxiety and depression, so these should be used with care in combination with 
thorough psychological/psychiatric assessment. 
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Introduction 
Chronic Fatigue Syndrome (CFS/ME) is common and disabling 1. Around 30% of 
adolescents have high levels of depressive symptoms on standardised questionnaires 2-4. A 
similar proportion have heightened anxiety, particularly social and separation anxiety 5. 
However, as the symptoms of anxiety (e.g. restlessness) and depression (e.g. fatigue, sleep 
problems) overlap with those of CFS/ME, symptom conflation may lead to inaccurate 
estimates when relying on questionnaires. In addition, adolescents with CFS/ME do not feel 
questionnaires (Patient Reported Outcome Measures, PROMs) accurately capture their 
symptoms 6. Some PROMs were designed for adults with no input from adolescents with 
CFS/ME 7. It is therefore not clear whether the published prevalence rates are accurate or not. 
This could be resolved with diagnostic interviews. Existing studies using diagnostic 
interviews have also found high rates of anxiety disorders and depression but are limited by 
small sample size and therefore potential bias 8,9 and are based on previous versions of the 
diagnostic criteria. 
  
The aim of this study was to (i) assess prevalence using diagnostic interviews with current 
DSM-5 criteria in a large clinical cohort and ii) assess the accuracy of commonly used 
PROMs in detecting mental health problems in this population.   
  
Patients and Method 
This was a cross-sectional study in a clinical cohort.  
 
Participants  
Consecutively referred adolescents, age 12-18, with a clinician confirmed diagnosis of 
CFS/ME at their initial assessment at a specialist paediatric CFS/ME team within the 
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National Health Service (NHS) in England were invited to participate. Recruitment spanned 
September 2016 to February 2019.  Exclusion criteria were (1) having learning difficulties 
which precluded the completion of the study measures and (2) being unable to complete the 
diagnostic interview due to the functional impact of their CFS/ME or due to insufficient 
English ability. After 6 months we adapted recruitment to include participants of the 
MAGENTA randomised control trial 10 (see online supplementary materials appendix 1 for 
further details).   
 
Measures 
Self-reported age, sex, ethnicity and school attendance were collected routinely at 
clinical assessment. 
 
KSADS - The Kiddie Schedule for Affective Disorders and Schizophrenia 11 is a semi-
structured diagnostic interview for children and adolescents age 6-18. It is the gold standard 
instrument for diagnosing depression 12,13. We focused on present psychiatric disorders (not 
previous, lifetime disorders). We used the following sections: MDD, panic disorder, 
agoraphobia, separation anxiety disorder, social anxiety disorder, phobic disorders, 
generalised anxiety disorder, obsessive compulsive disorder, posttraumatic stress disorder, 
eating disorders, and substance-related disorders 14. We did not screen for: psychosis, conduct 
disorder, attention deficit hyperactivity disorder, developmental disorders, enuresis and 
encopresis, nor did we screen for mania or disruptive mood dysregulation disorder which 
require historical information.  
 
Interviews were conducted by closely supervised research assistants (psychology 
students) who had completed a two-day training course. Following each interview, the 
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interviewer made a provisional diagnostic conclusion, which was reviewed and discussed 
with an experienced clinical psychologist (ML).  
 
RCADS – The Revised Children’s Anxiety and Depression Scale 15 is made up of 47 items, of 
which 10 ask about depression. Respondents rate each item on a 0-3 scale, and the total score 
is summed to give a depression score, where a higher score indicates greater depressive 
symptoms. Raw scores can be converted to age- and gender-adjusted T scores, which have a 
mean of 50 and a standard deviation of 10 using standardised tables. The RCADS has strong 
psychometric properties16,17, and good convergent validity with the KSADS 18.Adolescents 
and parents completed the RCADS and RCADS-P respectively. A briefer, 25 item version of 
the RCADS and RCADS-P were also tested in the current study.    
 
HADS – The Hospital Anxiety and Depression Scale 19 has 14 items: 7 depressive and 7 
anxiety items. The HADS was designed to minimise overlap with physical disorders by 
excluding somatic symptoms. It has been validated for use with adolescents and has 
acceptable psychometric properties in this population 20. Respondents rate items on a 0-3 
scale, and the items for each subscale are summed to give a total score, with higher scores 
indicating more symptoms.  
 
SCAS - The Spence Children’s Anxiety Scale 21,22 is a 45-item self-report scale 
designed to measure symptoms relating to DSM-IV separation anxiety, social phobia, 
obsessive-compulsive disorder, panic-agoraphobia, generalised anxiety and fears of 
physical injury 23. Each item is scored on a 0 (never) - 3 (always) scale. The SCAS 
contains 7 positive filler questions, not included in the total score. The 38 anxiety items 
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are summed, generating a total score out of a possible 114, with a higher score 
indicating greater anxiety. The SCAS has good psychometric properties 24. 
 
Fatigue – CFQ: The Chalder Fatigue Questionnaire 25 has 11 items, and responses are 
on a 0 (less than usual) – 3 (much more than usual) scale. Responses are summed to 
create a total score. Higher scores indicate more fatigue. It has good reliability and 
validity in CFS samples 26 and has been used as an outcome measure adolescents with 
CFS 27,28. 
 
Disability - SF36-PFS: The 10 item Short Form-36 Physical Functioning Subscale 29 
has 3 response options per item; 0 (yes limited a lot), 5 (yes, limited a little), and 10 
(no, not limited at all). Responses are summed, resulting in a total score out of a 
possible 100. Higher scores indicate better physical functioning. The psychometric 
properties of this scale are acceptable in adolescents with CFS 30.   
 
Ethical Approval 
Ethical approval was granted by the NHS Health Research Authority (16/SW/036) and 
the Department of Psychology at the University of Bath (16-203). The MAGENTA trial 
was approved by the NHS Health Research Authority (15/SW/0124).  
 
Procedure 
Potential participants were provided with a participant information sheet at their initial 
clinical assessment and offered the opportunity to agree to be contacted by the research 
team via telephone or email. Interested participants were provided with further 
information, and we subsequently obtained verbal consent and written consent, either 
 
7 
 
online via REDCap (Research Electronic Data Capture 31) or pen-and-paper. For 
participants who were <16 years old, parental consent and adolescent assent was 
obtained.  
 
Those participants recruited within the MAGENTA trial were assessed for eligibility for 
the trial by their assessing clinician (eligibility criteria are detailed in the study 
protocol10). Eligible patients who consented to be contacted were subsequently given 
further information about the study by a research nurse over the telephone, who obtained 
consent/assent via REDCap. From February 2017, this included consenting to participate 
in the KSADS interview for those participants of the MAGENTA trial who were ≥ 12 
years old.  
 
Participants provided consent to use data collected from the following clinical PROMs 
completed prior to first clinical assessment: SCAS, HADS, the CFQ and the SF36PFS. 
After recruitment, participants completed the RCADS. Participants interviewed as part of 
the MAGENTA trial did not complete the RCADS.  
 
The KSADS interview was conducted via Skype (N = 48, 29.3%), telephone (N = 89, 
54.3%), at the hospital site (N = 13, 7.9%), or the participant’s home (N = 10, 6.1%), 
according to participant preference. The KSADS has been administered by telephone in 
other studies 32,33, and diagnostic interviews have been administered via 
videoconferencing and telephone in chronic illness samples to minimise participant 
burden 34. Participants were given the option of being interviewed with a parent present. 
If they opted to be interviewed alone (N = 31, 18.9%), the parent was briefly interviewed 
separately. The questions asked of parents when interviewed alone were focused on the 
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more observable, behavioural aspects of depression and anxiety, such as irritability, and 
were also informed by the areas that the adolescent interview had highlighted. Parents 
were invited to add any other concerns they had. The resultant information was 
integrated into a summary judgement by the interviewer; due to the internalising nature 
of depression and anxiety, adolescent report given more weight when there were 
discrepancies between self- and parent-report. Research assistants were trained to 
accommodate the needs of young people with CFS/ME; interviews were kept brief, 
participants could take a rest breaks whenever they wished, and the interview could be 
conducted over several sessions within the same week where needed. Interviews lasted 
between 9 and 199 minutes in total (mean 44.43, SD 28.39).  
 
Interviews were conducted by research assistants (psychology students) who had 
completed a two-day training course on administration. Specific emphasis was on 
training the interviewers how to ask about each symptom screened for on the KSADS in 
a manner appropriate to the context of CFS/ME. For example, when asking about 
anhedonia, questions were asked about what activities adolescents engaged in currently 
that gave them enjoyment, even if they were unable to do the enjoyable activities they 
usually would. Similarly, when questions about fatigue particularly emphasised the link 
between fatigue and other mood relevant symptoms and experiences.  
 
Research assistants were subsequently closely supervised, including of audio recordings 
of interviews. Following each interview, the interviewer made a provisional diagnostic 
conclusion, which was reviewed and discussed with an experienced mental health 
professional (ML) for all cases. ML attended a 2-day training course on KSADS 
administration at the outset of the study, including taking part in inter-rater reliability 
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exercises. Additionally, 23 (14%) interviews were checked by a second interviewer, 
blind to the conclusion made by the interviewer. Both raters agreed on 195 of 207 
(94.2%) diagnostic decisions, which is considered fair agreement (Cohen, 1960), κ = .20 
p = .007, 95% CI [-0.16, 0.56]. 
 
Data analysis 
Data were analysed using IBM SPSS Statistics 23 and MedCalc. Participants were classified 
as having DSM-5 defined MDD, panic, agoraphobia, separation anxiety, social anxiety, 
phobic, generalised anxiety, obsessive compulsive, or posttraumatic stress disorder based on 
the KSADS interview. Descriptive statistics were analysed to determine prevalence of 
anxiety disorders and MDD.  
 
The diagnostic interview, the KSADS, was the gold standard against which the questionnaire 
scores were compared. Receiver Operating Characteristic (ROC) curves were constructed 
using the DeLong method and the diagnostic accuracy of the RCADS-D, RCADS-any 
anxiety disorder, SCAS, HADS-D and HADS-A was quantified using the area under the 
ROC curve (AUC). An AUC of ≥ 0.7 was assumed to indicate at least moderate accuracy in 
identifying those who have depression/anxiety. For clinical purposes, sensitivity was 
considered more desirable than specificity; therefore, we sought the optimal threshold which 
had a sensitivity of ≥ 0.8 and specificity of ≥ 0.7.  
 
Results 
Of 375 patients who attended an initial clinical assessment appointment and were assessed as 
meeting the eligibility criteria, 263 (70.1%) agreed to further contact from the research team, 
and 185 (70.3%) of these consented to participate in the study, with 21 subsequently 
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withdrawing (See Figure 2). Those who were recruited were similar to those who were not 
recruited (i.e. eligible but not offered the opportunity to participate by clinicians, or declined 
consent to contact, see supplementary information Table S1.). Of the 164 patients (43.7% of 
those eligible) interviewed, most were female (70.1%). The mean age was 14.99 years, 
mainly White British participants (see table 1). Only 13 (7.9%) participants were attending 
school full time, with 67 (40.8%) participants attending less than 40% of the time and the 
participant mean score on the SF36PFS as a measure of disability was 51.66, which is 
comparable to other cohort studies in the same setting 2,27,35 (see supplementary materials 
table S2.). In almost all cases, a parent was interviewed as well as the adolescent themselves 
(N = 156, 95%). The majority (N = 140) were mothers. In 9 instances, fathers were 
interviewed, and both parents in 7 instances.  
 
[insert figure 1 and table 1 about here] 
 
Out of the 164 participants recruited, 58 (35.4%) met the criteria for at least one mental 
health diagnosis of whom 13 (7.9%) had Major Depressive Disorder (MDD) only, 25 
(15.2%) had an anxiety disorder only. Approximately a third (20, 34.5%) had both anxiety 
and depression which means that 33 participants (20%, 95% CI 13.1-27.1) met the criteria for 
MDD, and 45 participants (27.4%, 95% CI 20.4-34.4) met the criteria for at least one anxiety 
disorder (see table 2).  
 
Consistent with the predominance of females in the sample, more females than males were 
diagnosed with depression (N = 23, 69.7% female) and anxiety (N = 34, 75.6%). The mean 
age of those meeting diagnostic criteria on the KSADS was slightly higher than the overall 
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sample mean but not significantly so (Depression: mean difference = 0.22, 95% CI -0.34-
0.78, p = 0.435; Anxiety: mean difference = 0.41, 95% CI -0.08-0.90, p = 0.101).  
 
The most prevalent anxiety disorder types were social anxiety disorder (N = 19, 11.6%) and 
generalised anxiety disorder (N = 17, 10.4%). Fourteen (8.5%) had a phobic disorder with 4 
participants meeting the criteria for an animal phobia, 4 natural environment phobias (e.g. 
thunderstorms, heights), 1 blood/injection/injury phobia, and 5 situational type phobias (e.g. 
planes, elevators). Only 1 participant met the full diagnostic criteria for separation anxiety 
disorder, although a further 16 (9.8%) presented with subthreshold symptoms of separation 
anxiety. Thirty participants met the criteria for only one anxiety disorder diagnosis, with 11 
meeting criteria for two anxiety disorders, and 4 meeting the criteria for 3 anxiety disorders.  
 
Of the 33 diagnosed with co-morbid depression, the vast majority (N = 30, 90.9%) had 
significant fatigue which they perceived to be linked to and exacerbated by their mood, over 
and above fatigue from their CFS/ME. Furthermore, cognitive difficulties were fairly 
pervasive (N = 29, 87.9%). Most had depressed mood (N = 23, 69.7%) and/or psychomotor 
retardation or agitation (N = 23, 69.7%). Many also had difficulties sleeping (N = 21, 63.6%) 
and/or irritability (N = 21, 63.6%). Relatively few (N = 6, 18.2%) had suicidal thinking or 
feelings of worthlessness (N = 13, 39.4%). Anhedonia was described in just over 50% of the 
sample (see table 3).  
 
[insert tables 2 and 3 about here] 
 
All PROMs (i.e. the RCADS, HADS and SCAS) scored > 0.7 for area under the curve, AUC, 
indicating at least moderate accuracy (see table 4 and figures 2 and 3). The RCADS-A 
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performed the best and both the brief and full version were similar with little difference 
between the raw scores and the age- and gender-adjusted T scores. For all versions of the 
RCADS-A, we identified threshold scores reaching the required ≥ 0.8 sensitivity and ≥ 0.7 
specificity thresholds. We could not identify scores on the HADS-A and SCAS which 
reached these thresholds (see table 4). None of the depression measures were sufficiently 
accurate to reach the 0.8/0.7 requirement (see table 4).  
 
[insert table 4, Fig 2. and Fig 3. about here] 
 
Discussion 
This is the first large clinical cohort study to accurately measure both anxiety and depression 
using diagnostic interviews applying DSM-5 criteria in adolescents with CFS/ME. We found 
that 1 in 3 met the diagnostic criteria for a common mental health disorder. The majority of 
those who met the criteria for a mental health problem had both anxiety and depression; 20% 
of adolescents attending a specialist CFS/ME service meet the criteria for Major Depressive 
Disorder (MDD), and 27% the criteria for at least one anxiety disorder. Some meet the 
criteria for up to 3 co-occurring anxiety disorders. The high co-morbidity in this group 
suggests that if one is diagnosed, the other needs to be screened for. Unlike in other 
conditions, the PROMs weren’t sufficiently accurate, apart from the RCADS-A (self-report 
and parent versions) and even using the optimum cut-offs we identified will likely result in 
false positives and false negatives. 
 
Consistent with the epidemiology of CFS/ME36, we recruited more females than males. 
Despite the recruitment difficulties encountered (Loades et al BMC article), the participants 
recruited to this study were comparable to those recruited in other cohort studies and 
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randomised controlled trials in the same service setting (see supplementary materials Table 
S3.).   
 
This study is consistent with previous work which shows that depression and anxiety are 
higher in adolescents with CFS/ME5,37 8,9 than in healthy populations38,39.  The high rates of 
depression and anxiety seen in adolescents with CFS/ME could be due to a variety of factors 
including social loss 40-42, the inability to take part in activities40,41 or other underlying causal 
factors including shared genetic vulnerability43 and previous trauma44,45. Alternatively, a 
tendency to avoid anxiety-provoking situations, such as phobic stimuli or physical activity 
following a viral infection, could independently contribute to both anxiety and CFS/ME, for 
instance 46,47. 
 
We found high rates of anxiety disorders. This is particularly striking given that the KSADS 
applies stricter criteria than the Anxiety Diagnostic Interview Schedule (ADIS), which is 
most commonly used in anxiety studies 48. We did not show the high rates of separation 
anxiety found in previous work5. This may be because previous studies recruited younger 
participants, more likely to be experiencing separation anxiety disorder 49. Alternatively, it 
may be because of the reliance of previous studies on questionnaires, which meant that they 
were unable to distinguish between those with raised separation fears (which were highly 
prevalent in our sample) and those meeting the full diagnostic criteria for separation anxiety 
disorder. The level of specific phobia was comparable to general population samples of 
adolescents 50,51. The high levels of Generalised Anxiety Disorder are a new finding. This 
may be because of a general tendency to avoid anxiety-provoking situations46,47 or shared 
vulnerability52.  
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In those adolescents who were depressed, the pattern of symptoms was different to that 
commonly found in samples recruited via Child and Adolescent Mental Health Services 53,54. 
Rates of suicidal ideation and feelings of worthlessness were particularly low, which may be 
due to referral criteria for different specialist services, with those who report suicidal ideation 
more likely to be referred to mental health services. Rates of somatic symptoms including 
fatigue and cognitive difficulties were extensive in our sample, which are also common in 
adolescents with CFS/ME 35 and may be compounded in those who have co-morbid 
depression. It may also be that there are different subtypes of depression, including an 
inflammation-linked somatic subtype, which is more frequent in CFS/ME55. Our findings 
suggest that depression in adolescents CFS/ME may be characterised less by negative self-
perceptions and self-injurious behaviours and more by anhedonia and somatic symptoms.   
 
Whilst this is the first study to accurately define the prevalence of both anxiety and 
depression in CFS/ME, the high rate of comorbidity between the two is perhaps not 
surprising given the co-occurrence in healthy adolescents56. It does however mean that 
clinicians and clinical services ought to screen for both mood and anxiety disorders when 
planning treatment.  
 
As the KSADS diagnostic interview is too resource intensive for use in most routine clinical 
care settings, a screening measure that is sufficiently accurate and appropriate for the 
population is urgently needed. Apart from the RCADS-anxiety, the PROMs we examined did 
not meet our pre-specified criteria for accuracy. It is encouraging that both the self- and 
parent-report versions of the RCADS anxiety subscale (37 items), and the brief versions of 
this (15 items) did meet these criteria. In CFS/ME, reducing burden on patients is of utmost 
importance, and using the brief version (although this is at the cost of information about 
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specific anxiety disorder types) and using parent informants where adolescents are too unwell 
to complete the questionnaire themselves could be useful. The RCADS-depression subscale 
did not meet the criteria for accuracy. Furthermore, the HADS did not meet the required 
accuracy criteria for either depression or anxiety; we would therefore recommend that 
services use other PROMs such as the RCADS for anxiety. The HADS was developed for 
adults and then validated for use in adolescents, whilst the RCADS was specifically 
developed for children and adolescents and may therefore be more developmentally 
appropriate. A more accurate self-report measure of depression symptoms among adolescents 
with CFS/ME is needed.  The Mood and Feelings Questionnaire 57 which is the gold standard 
questionnaire for screening for depression in adolescents 58 and may overlap less with the 
core symptoms of CFS/ME could be worth investigating.    
 
Strengths and Limitations 
This is a considerably larger study than has previously been undertaken in adolescents with 
CFS/ME. However, we did not include under 12s, and can’t make any conclusions about 
anxiety and depression in children. We used diagnostic interviews, assessed the latest DSM-5 
criteria and aimed to recruit all eligible patients seen within the largest specialist paediatric 
CFS/ME clinic in the UK. Whilst our sample is large, many patients declined to participate so 
our sample may not be fully representative of the population seen in this clinic or wider 
services. Furthermore, our findings may not apply to settings other than specialist services. 
Finally, whilst the KSADS is the best diagnostic instrument for diagnosing depression, it may 
not always be 100%. Accuracy depends on diagnostic judgements by trained raters. This 
needs to be acknowledged but we minimised this possibility through training and individual 
case review. 
 
 
16 
 
Conclusion 
A substantial minority of adolescents with CFS/ME meet diagnostic criteria for a co-morbid 
major depressive disorder, or an anxiety disorder (generalised anxiety, social anxiety and 
specific phobia are most common) or both. Identifying patients who are experiencing mental 
health problems is key to treatment for both CFS/ME and psychological distress, and to 
enabling recovery and maximising functioning. Clinicians need to be aware that symptoms 
typically associated with depression (such as suicidal thinking) and anxiety are not 
necessarily present in adolescents with CFS/ME. Many patients have both anxiety and 
depression; therefore, clinicians should screen for one if they find the other. A full clinical 
assessment should be used alongside the RCADS questionnaire. Clinicians in paediatric 
settings may benefit from additional training in identifying mental health problems in 
adolescents with CFS/ME specifically. A combination of qualitative and longitudinal 
epidemiological research would shed further light on the factors which contribute to anxiety 
amongst this population. 
 
  
 
17 
 
Acknowledgements 
 
The authors would like to thank all the young people and families who took part in this study, 
and healthcare professionals in at the recruitment site who supported the study. The authors 
are also grateful to Soraya Safazadeh, Nikos Vrontaras, Matilda Wyn-Griffiths and Jiedi Lei 
for their help with data collection. The authors would like to extend their thanks to Anna 
Brooke for her support with navigating ethics processes, and to Richard Morris for his 
statistical advice.  
  
 
18 
 
Table 1. Characteristics of the sample 
Gender Male 
Female 
49 (29.9%) 
115 (70.1%) 
 
    
Ethnic origin White British 
Unspecified 
146 (89.0%) 
10 (6.1%) 
 
 Other White  
Other British  
6 (3.7%) 
1 (0.6%) 
 
 Pakistani 1 (0.6%)  
  
Range 
 
Mean (SD) 
 
Cronbach’s α 
Age (years) 12-18 14.99 (1.50)  
SCAS total 3-99 34.44 (17.97) .93 
HADS-D total 
RCADS-A  
RCADS-D 
CFQ 
0-18 
5-78 
2-27 
11-33 
7.85 (3.76) 
35.28 (20.73) 
15.02 (5.38) 
25.25 (4.47) 
.76 
.96 
.84 
.83 
SF36PFS 0-100 
 
51.66 (24.04) .90 
 
CFQ = Chalder Fatigue Questionnaire, HADS-A = Hospital Anxiety and Depression Scale-
Anxiety, HADS-D = Hospital Anxiety and Depression Scale-Depression, RCADS-A = 
Revised Children’s Anxiety and Depression Scale-Any Anxiety, RCADS-D = Revised 
Children’s Anxiety and Depression Scale-Depression, SCAS = Spence Children’s Anxiety 
Scale, SF36PFS = Short Form 36 Physical Functioning Subscale 
  
 
19 
 
Table 2. Number of participants meeting DSM-5 diagnostic criteria on the KSADS 
Disorder Participants who received diagnosis - 
N (%) 
Major Depressive Disorder 33 (20.1) 
Any anxiety disorder 45 (27.4) 
Panic 6 (3.7) 
Agoraphobia 4 (2.4) 
Separation anxiety 1 (0.6) 
Social anxiety 19 (11.6) 
Phobia 14 (8.5) 
Generalised Anxiety Disorder (GAD) 17 (10.4) 
Obsessive Compulsive Disorder (OCD)a 3 (1.8) 
Eating Disorder 0 
Post Traumatic Stress Disorder (PTSD)a 1 (0.6) 
aOCD was included as an anxiety disorder, but PTSD was not, as this is consistent with the 
PROMs used 
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Table 3. Frequency of threshold symptoms of depression on the KSADS in those diagnosed 
with Major Depressive Disorder (MDD) – data shown as N (%) 
DSM Symptom Yes 
Depressed mood 23 (69.7) 
Irritable mood 21 (63.6) 
Anhedonia 18 (54.5) 
Appetite/weight change 17 (51.5) 
Insomnia/hypersomnia 21 (63.6) 
Psychomotor agitation/retardation 23 (69.7) 
Fatiguea 30 (90.9) 
Feelings of worthlessness/excessive or inappropriate guilt 13 (39.4) 
Reduced concentration/slowed thinking/indecisiveness 29 (87.9) 
Recurrent thoughts of death/suicidal ideation/suicide attempt 6 (18.2) 
aFatigue was scored as threshold only if it was perceived to be linked to mood by (1) becoming more prominent 
at the onset of the low mood episode, and/or (2) tending to be worse when mood was worse.  
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Table 4. ROC analysis for PROMs 
 Measure AUC S.E. of 
AUC 
95% 
CI for 
AUC 
Z-
statistic 
for 
AUC 
Optimum 
threshold 
for 
diagnosis 
Sensitivity Specificity 
 
Adolescent Self-Reported Measures 
Depression 
(MDD) 
RCADS-D 
raw score 
0.789 0.0464 0.690-
0.869 
6.238 >14 
>15 
92.00 
72.00 
59.38 
68.75 
RCADS-D 
t-score 
0.787 0.0485 0.685-
0.869 
5.929 >68 
>69 
80.00 
72.00 
63.33 
66.67 
HADS-D 0.714 0.0425 0.636-
0.783 
5.032 >7 
>8 
80.65 
67.74 
55.20 
61.60 
Anxiety 
(any 
anxiety 
disorder 
diagnosis) 
RCADS-A 
(37 item) 
raw score 
0.879 0.0357 0.792-
0.938 
10.602 >37 
>38 
86.67 
80.00 
72.88 
76.27 
RCADS-A 
(37 item) t-
score 
0.889 0.0347 0.802-
0.947 
11.221 >55 
>56 
86.67 
86.67 
80 
81.82 
RCADS-A 
(15 item) 
raw score 
0.890 0.0337 0.806-
0.946 
11.582 >10 
>11 
>12 
93.33 
90.00 
80 
72.88 
74.58 
77.97 
RCADS-A 
(15 item) t-
score 
0.889 0.0347 0.802-
0.947 
11.221 >56 86.67 81.82 
HADS-A 0.774 0.0403 0.700-
0.837 
6.795 >9 
>10 
83.33 
71.43 
60.18 
68.14 
SCAS 0.744 0.0449 0.665-
0.814 
5.438 >37 
>39 
76.32 
71.05 
70.48 
76.19 
 
Parent Informant-Reported Measures 
Depression 
(MDD) 
RCADSP-D 
raw score 
0.780 0.0517 0.688-
0.869 
5.582 > 15 69.6 79.7 
RCADSP D 
t-score 
0.787 0.0485 0.685-
0.869 
5.929 >68 80 63.33 
Anxiety 
(any 
anxiety 
disorder 
diagnosis) 
RCADSP-A 
(37 item) 
0.858 0.0417 0.765-
0.924 
8.565 >31 83.33 76.36 
RCADSP-A 
(37 item) t-
score 
0.858 0.0438 0.762-
0.925 
8.162 >62 
>64 
83.33 
80.00 
78.43 
80.39 
RCADSP-A 
(15 item) 
0.780 0.0517 0.765-
0.922 
8.449 >9 80.00 75.44 
RCADSP-A 
(15 item) t-
score 
0.861 0.0421 0.767-
0.928 
8.572 >58 80.00 75.00 
Note: Bold indicates that the minimum required 0.8 sensitivity/0.7 specificity criterion is met by this threshold 
score 
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Figure 1. Consort diagram showing number of participants at each stage of recruitment 
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Figure 2. Receiver Operating Curves for depression measures 
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Figure 3. Receiver Operating Curves for anxiety measures 
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